On October 5, 2023 Agenus Inc. (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, reported that the Company will host a corporate event to discuss advancements in its botensilimab/balstilimab (BOT/BAL) program at the upcoming European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Conference on Sunday, October 22, 2023 (Press release, Agenus, OCT 5, 2023, View Source [SID1234635692]). Agenus will provide updates from the ongoing BOT/BAL clinical program, including in neoadjuvant colorectal cancer and pancreatic cancer. A live webcast of the event will be available.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Speakers include:

Alexander Eggermont, M.D., Ph.D., University Medical Center, Utrecht, Princess Maxima Center for Pediatric Oncology, Comprehensive Cancer Center
Marwan Fakih, M.D., City of Hope
Manuel Hidalgo, M.D., Ph.D., Weill Cornell Medicine
Pashtoon Kasi, M.D., M.S., Weill Cornell Medicine
Breelyn Wilky, M.D., University of Colorado Medicine
Steven O’Day, M.D., Chief Medical Officer, Agenus
Todd Yancey, M.D., Senior Advisor, Agenus
Event Details

Date: Sunday, October 22, 2023

Time: 19:00 – 21:00 CEST (1:00 p.m. – 3:00 p.m. EDT)

To register for the webcast, please click here.

On October 5, 2023 Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, reported its plans to host a Virtual R&D Event with Key Opinion Leaders (KOLs) on October 17, 2023 (Press release, Vivoryon Therapeutics, OCT 5, 2023, View Source [SID1234635690]). In addition, the Company’s management will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event details:

Jefferies Biotech CNS/Neuro Summit (October 11 – 12, 2023)

Date: October 11, 2023

Presentation time: 2:00pm EDT / 8:00pm CEST

Venue: New York; NY, USA

Virtual R&D Event with Key Opinion Leaders

Date: October 17, 2023
Time: 7:30am EDT / 1:30pm CEST
Featured presentations and a moderated panel discussion on the design and rationale of the VIVIAD Phase 2b study of varoglutamstat in Alzheimer’s disease followed by Q&A
For further information and pre-registration, please visit View Source

Webcasts of the conference presentation and the Virtual R&D Event will be available via the "Presentations & Webcasts" page in the Investor Relations section on the Company’s website at www.vivoryon.com and will be archived on the Company’s website for 90 days (conference), respectively one year (R&D Event) following the events.

On October 5, 2023 Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, reported that members of its executive team will participate at the following investor conferences (Press release, Vedanta Biosciences, OCT 5, 2023, View Source [SID1234635689]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BMO Life Sciences Private Company Showcase

Presentation Date: October 12, 2023

Presentation Time: 2:55 p.m. ET

Location: The New Your Times Building, New York, NY

Leerink Partners Biopharma Private Company Connect

Dates: October 25-26, 2023

Virtual 1×1 meetings only

On October 5, 2023 Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, reported that long-term data regarding Cesium-131 brachytherapy in the treatment of prostate cancer, as well as preliminary long-term data of Cesium-131 utilized in salvage treatment of recurrent cervical and uterine cancers were presented at the American Society for Radiation Oncology’s (ASTRO) Annual Conference held in San Diego, from October 1-4, 2023 (Press release, Perspective Therapeutics, OCT 5, 2023, View Source [SID1234635687]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first presentation, entitled "Long-Term Urinary Toxicity Follow-Up of Combined External Beam Radiation and Cs-131 LDR Brachytherapy Boost for Prostate Cancer," was presented by Mohamed Abdelhakiem, MD from the UPMC Hillman Cancer Center in Pittsburgh, PA. The presentation described urinary data collected from 341 patients treated with Cesium-131 between 2006 and 2022.

The second presentation, entitled "Cesium-131 Low-Dose Rate Interstitial Brachytherapy as a Salvage Re-Irradiation Technique in Treating Cervical and Uterine Cancer Pelvic Recurrence with Prior History of Pelvic Radiation," was presented by Zeta Chow, MD, MS from the University of Kentucky in Lexington, KY. The aim of the study was to report local cancer control rates and the toxicity profile of Cesium 131 brachytherapy as a salvage re-irradiation option for patients with recurrent disease. The authors concluded that Cesium-131 brachytherapy is a promising alternative to pelvic exenteration, which can be a significant surgical procedure.

"We’re excited that UPMC’s long term data on Cesium-131 brachytherapy for prostate cancer was included at this year’s ASTRO meeting," said Thijs Spoor, Perspective’s Chief Executive Officer. "ASTRO’s inclusion of the University of Kentucky’s promising data describing Cesium-131 brachytherapy in a challenging group of gynecological patients reinforces its value as the isotope of choice for brachytherapy treatment in multiple tumors."

Perspective Therapeutics is the world’s only producer of Cesium-131 seeds for brachytherapy which provide expanding internal radiation treatment options throughout the body for prostate cancer as well as difficult to treat lung, brain, gynecological, head and neck, pelvic, and colorectal cancers.

Additional details about these presentations can be found on the ASTRO website (www.astro.org).

On October 5, 2023 Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, reported that the first patient has been dosed in the Phase 1/2 dose escalation/dose expansion study of ONCT-534, the company’s dual-action androgen receptor inhibitor (Press release, Oncternal Therapeutics, OCT 5, 2023, View Source [SID1234635686]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The dosing of the first patient with ONCT-534 is an important milestone for patients suffering from advanced prostate cancer who have relapsed or are refractory after treatment with AR signaling inhibitors," said Salim Yazji, M.D., Oncternal’s Chief Medical Officer. "Preclinical studies suggest that ONCT-534 may address important tumor escape mechanisms that result in resistance to currently available AR inhibitors, such as enzalutamide or abiraterone. We intend to advance the dose escalation portion of the Phase 1/2 Study ONCT-534-101 quickly, and we will be enrolling patients in sites across the U.S. over the coming weeks, and in the United Kingdom in early 2024. We expect to report initial clinical data in the first half of 2024."

ONCT-534 is a dual-action androgen receptor inhibitor (DAARI) that interacts with both the N-terminal domain and the ligand-binding domain (LBD) of the androgen receptor (AR), inhibiting cell growth and inducing AR degradation. Preclinical studies have shown activity in prostate cancer models against both unmutated AR, and against multiple mutations, including AR amplification, mutations in the AR LBD, and splice variants with loss of the AR LBD.

About Study ONCT-534-101
Study ONCT-534-101 is a Phase 1/2, single-arm, open-label, multi-center study to evaluate the safety and tolerability, pharmacokinetics, and anti-tumor activity of ONCT-534 in patients with metastatic castration-resistant prostate cancer (mCRPC) who have relapsed or are refractory to approved androgen receptor signaling inhibitors (ARSIs) including enzalutamide, abiraterone, apalutamide and darolutamide. After the safety and tolerability of ONCT-534 have been assessed to select the recommended Phase 2 dose (RP2D) in Phase 1, Phase 2 will commence to further validate the dose and evaluate the safety and efficacy of ONCT-534.